These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 9808145

  • 1. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [Abstract] [Full Text] [Related]

  • 2. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

  • 3. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
    Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM.
    Clin J Am Soc Nephrol; 2014 Sep 05; 9(9):1620-6. PubMed ID: 24970869
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E, Finch J, Ritter C, Takahashi F.
    Am J Kidney Dis; 1998 Oct 05; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [Abstract] [Full Text] [Related]

  • 6. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar 05; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

  • 7. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Mar 05; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 8. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
    Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.
    Am J Kidney Dis; 1998 Oct 05; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
    [Abstract] [Full Text] [Related]

  • 9. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov 05; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 10. Spotlight on paricalcitol in secondary hyperparathyroidism.
    Robinson DM, Scott LJ.
    Treat Endocrinol; 2005 Nov 05; 4(3):185-6. PubMed ID: 15898824
    [Abstract] [Full Text] [Related]

  • 11. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov 05; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 12. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct 05; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 13. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Oct 05; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 14. 1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.
    St-Arnaud R, Arabian A, Yu VW, Akhouayri O, Knutson JC, Strugnell SA.
    J Endocrinol Invest; 2008 Aug 05; 31(8):711-7. PubMed ID: 18852532
    [Abstract] [Full Text] [Related]

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 05; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 16. Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.
    Barton Pai A, Lin S, Arruda JA, Lau AH.
    Int J Artif Organs; 2003 Jun 05; 26(6):484-90. PubMed ID: 12866654
    [Abstract] [Full Text] [Related]

  • 17. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM.
    Kidney Int Suppl; 2010 Aug 05; (117):S33-6. PubMed ID: 20671742
    [Abstract] [Full Text] [Related]

  • 18. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
    Shuja SB, Raja RM.
    Adv Perit Dial; 2003 Aug 05; 19():231-5. PubMed ID: 14763069
    [Abstract] [Full Text] [Related]

  • 19. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun 05; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Jun 05; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.